Findings published in disorders opened of periodical BMC Musculoskeletal of the access shows that the classroom the most delayed of the used drugs to treat the arthritis rheumatoid (RA) is better of the one than anti-inflammatory standard.
The RA is a chronic illness, debilitating, inflammatory of the junctions, that are dealt generally with the drugs anti-inflammatory such as methotrexate or steroids. However, the discovery that a protein of the white stacks of blood, known as the alpha of the factor of the necrosis of tumour (TNF), it caused some of the symptoms of the RA, lead to the development of the drugs of the novel that obstruct TNF. This group of the drugs, known as anti-TNF? the drugs (that they include infliximab, etanercept and adalimumab), are used now generally to treat the RA.
However, did not have no comparison ‘ head-to-head ‘ of anti-TNF new? drugs in the terms of the security or efficacy for the treatment of the RA.
Alberto Alonso-Ruiz of the hospital of Cruces in Barakaldo, Vizcaya, Spain and colleagues in the hospital of Donostia and the university of the country basque, procurarados sistematicamente for the research on the use of anti-TNF? drugs in patients of the RA. They had found thirteen experimentations clinical to include on 7000 patients. The investigators had analyzed then the experimental results, the patient benefits sistematicamente registering and the side effects for different doses of anti-TNF of three main pipes? drugs.
The analysis of the agreed results of all the thirteen experimentations showed to this anti-TNF? the drugs, given in recommended doses, were better of the one than the usual treatments, such as methotrexate, to treat the RA. The patients who had seen previously little benefit of methotrexate alone had shown a better reply with anti-TNF combined? positive therapy of methotrexate.
The team found that all the three drugs were very similar in its benefits same in doses more highly of the one than those recommended by the manufacturer of the drug. This classroom of the drugs, when very efficient, it more has a raised frequency of side-effects adverse. The patients in infliximab were more probable to the drop are of an experimentation for cause of these side effects. In the contrast, the patients who use etanercept had had the withdrawal tax lowest. The investigators indicate that this could be because this drug was not told as being used in dosage more highly of the one than recommended in the experimentations.
“Anti-TNF? the drugs such as infliximab, adalimumab and etanercept that all seem to be efficient in the treatment of the RA “had said Alonso-Ruiz. “to execute comparisons of new drugs it is vital to measure adverse relationships of safety/efficacy and to monitor side-effects”
The article was adaptou today for Medical Notice of the release of the original press.
1. Drugs of the factor of the necrosis of the tumor in the arthritis rheumatoid: systematic revision and goal-analysis of efficacy and the security
Alberto Alonso-Ruiz, Jose Ignacio Pijoan, Eukene Ansuategui, Arantxa Urkaregi, Marcelo Calabozo and Antonio Quintana
Disorders of BMC Musculoskeletal (in the press)
Available article in the Web site of the periodical: http://www.biomedcentral.com/bmcmusculoskeletdisord/
All the articles are available free of the load, in accordance with the open politics of the access of the central office of BioMed.
2. Disorders of BMC Musculoskeletal is an open periodical of the access that publishes pair-reviewed articles original of the research in all the aspects of the prevention, the diagnosis and the musculoskeletal management of disorders and associates, as.well.as genetics, pathophysiology, and epidemiology molecular related. Disorders of BMC Musculoskeletal (ISSN 1471-2474) is indexed/tracked/covered for PubMed, MEDLINE, CAS, Scopus, BASES, scientific Thomson (ISI) and scholar of Google.
3. The central office of BioMed (http://www.biomedcentral.com/) is a house publishing in independent line committed to supply the immediate access without load to the research that biological and medical pair-magazine publishes. This commitment is based on the sight that the open access to the research is essential to the fast and efficient communication of science.
Source: Charlotte Webber
Central officeBioMed
Filled under: Uncategorized
Leave a comment or two
